Loading...
XNASKZIA
Market cap373mUSD
Jan 10, Last price  
1.58USD
1D
-6.51%
1Q
289.16%
Jan 2017
-73.04%
Name

Kazia Therapeutics Ltd

Chart & Performance

D1W1MN
XNAS:KZIA chart
P/E
—
P/S
263.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
330.27%
Revenues
2m
+415,755.86%
17,606,61913,504,50017,313,61513,275,21211,147,0009,908,0002,025,0002,450,0001,067,31987,00089,0004,071,0008,788,23713,1081,5651,06115,182,711255552,308,000
Net income
-27m
L+30.85%
00-20,002,9140-18,928,000-12,345,000-6,498,0001,309,000-1,030,852-7,467,319-7,138,596-12,062,000-10,670,377-6,039,000-10,270,000-12,467,000-8,421,960-24,647,815-20,465,180-26,778,000
CFO
-10m
L-36.78%
00-14,625,4950-20,602,000-16,606,000-8,703,000643,000-8,793,734-5,709,334-5,759,206-11,980,000-11,434,698-8,661,000-6,714,000-8,810,000-9,110,516-22,761,000-15,156,157-9,581,000
Earnings
Feb 20, 2025

Profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
URL
https://www.kaziatherapeutics.com/
IPO date
Sep 01, 1994
Employees
12
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
2,308
415,755.86%
555
2,120.00%
25
-100.00%
Cost of revenue
30,943
24,147
24,891
Unusual Expense (Income)
NOPBT
(28,635)
(24,147)
(24,891)
NOPBT Margin
Operating Taxes
(271)
271
(368)
Tax Rate
NOPAT
(28,364)
(24,418)
(24,523)
Net income
(26,778)
30.85%
(20,465)
-16.97%
(24,648)
192.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,580
12,972
3,726
BB yield
-60.68%
-6.70%
Debt
Debt current
634
1,796
1,841
Long-term debt
Deferred revenue
Other long-term liabilities
3,787
8,469
9,075
Net debt
(1,023)
(3,445)
(5,520)
Cash flow
Cash from operating activities
(9,581)
(15,156)
(22,761)
CAPEX
Cash from investing activities
(2,365)
Cash from financing activities
5,985
12,972
3,726
FCF
(9,346)
(24,418)
(24,523)
Balance
Cash
1,657
5,241
7,361
Long term investments
Excess cash
1,542
5,241
7,361
Stockholders' equity
(10,017)
12,051
18,638
Invested Capital
4,421
17,074
22,218
ROIC
ROCE
800.31%
EV
Common stock shares outstanding
18,428
13,247
Price
0.23
-80.29%
1.16
-72.38%
4.20
-57.40%
Market cap
21,377
-61.58%
55,636
-95.20%
EV
17,932
50,116
EBITDA
(26,766)
(22,277)
(22,938)
EV/EBITDA
Interest
2
Interest/NOPBT